-
Something wrong with this record ?
Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19
M. Bohoněk, J. Máca, J. Sagan, D. Řezáč, V. Fridrich, A. Burantová, D. Kutáč, P. Vabroušek, J. Kubů, A. Chrdle, K. Volfová, Š. Blahutová, I. Rychlík, K. Vonášková, R. Majerčin, R. Králová, P. Štěpánek, M. Holub
Language English Country England, Great Britain
Document type Journal Article, Observational Study
Grant support
MO1012
Ministerstvo Obrany České Republiky
MO1012
Ministerstvo Obrany České Republiky
NLK
BioMedCentral
from 2004-12-01
BioMedCentral Open Access
from 2004
Directory of Open Access Journals
from 2004
Free Medical Journals
from 2004
PubMed Central
from 2004
Europe PubMed Central
from 2004
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2004-08-01
Open Access Digital Library
from 2004-01-01
Open Access Digital Library
from 2004-01-01
Medline Complete (EBSCOhost)
from 2004-08-26
Health & Medicine (ProQuest)
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2004
Springer Nature OA/Free Journals
from 2004-12-01
- MeSH
- COVID-19 * therapy mortality MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Immunization, Passive * methods MeSH
- Antibodies, Viral blood MeSH
- Retrospective Studies MeSH
- SARS-CoV-2 * immunology MeSH
- Aged MeSH
- COVID-19 Serotherapy * MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Geographicals
- Czech Republic MeSH
PURPOSE: Convalescent plasma (CP) collected from people who recovered from COVID-19 became a rapidly available treatment modality in numerous countries, including the Czech Republic. The aims of our study were to evaluate the effectiveness and safety of CP in the treatment of COVID-19. METHODS: This retrospective observational study involved six Czech hospitals. This study enrolled patients with and without CP treatment who were hospitalized between April 2020 and April 2021. Propensity score matching and logistic regression analysis were performed to evaluate the influence of CP administration and its timing on the in-hospital survival of COVID-19 patients. RESULTS: A total of 1,498 patients were enrolled in the study; 406 (27%) were administered CP, and 1,092 (73%) were not treated with CP. The propensity score-matched control group consisted of 1,218 subjects. The survival of patients treated with CP was 79%, while that of patients in the matched control group was 62% (P<0.001). Moreover, the chance of survival was significantly greater when CP was administered within three days after the onset of COVID-19 symptoms than when CP was administered after four or more days (87% vs. 76%, P <0.001). In addition, adverse effects related to CP administration were recorded in only 2% of patients and were considered mild in all patients. CONCLUSIONS: Our study demonstrated that the administration of CP was safe and possibly associated with positive effects that were more pronounced if CP was administered within the first three days after the onset of COVID-19 symptoms.
Department of Anesthesiology and Resuscitation Regional Hospital Jičín Jičín Czech Republic
Department of Anesthesiology and Resuscitation Regional Hospital Náchod Náchod Czech Republic
Department of Clinical Studies Faculty of Medicine University of Ostrava Ostrava Czech Republic
Department of Infectious Diseases České Budejovice Hospital České Budějovice Czech Republic
Department of Science and Research University Hospital Bulovka Prague Prague Czech Republic
Faculty of Biomedical Engineering Czech Technical University Prague Prague Czech Republic
Faculty of Health and Social Sciences University of South Bohemia České Budějovice Czech Republic
The 7th Field Hospital of the Army of the Czech Republic Hradec Králové Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004099
- 003
- CZ-PrNML
- 005
- 20250206105128.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12985-024-02475-y $2 doi
- 035 __
- $a (PubMed)39350163
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Bohoněk, Miloš $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Prague, Czech Republic $u Faculty of Biomedical Engineering, Czech Technical University in Prague, Prague, Czech Republic
- 245 10
- $a Convalescent anti-SARS-CoV-2 plasma for the treatment of patients with COVID-19: a retrospective study RESCOVID-19 / $c M. Bohoněk, J. Máca, J. Sagan, D. Řezáč, V. Fridrich, A. Burantová, D. Kutáč, P. Vabroušek, J. Kubů, A. Chrdle, K. Volfová, Š. Blahutová, I. Rychlík, K. Vonášková, R. Majerčin, R. Králová, P. Štěpánek, M. Holub
- 520 9_
- $a PURPOSE: Convalescent plasma (CP) collected from people who recovered from COVID-19 became a rapidly available treatment modality in numerous countries, including the Czech Republic. The aims of our study were to evaluate the effectiveness and safety of CP in the treatment of COVID-19. METHODS: This retrospective observational study involved six Czech hospitals. This study enrolled patients with and without CP treatment who were hospitalized between April 2020 and April 2021. Propensity score matching and logistic regression analysis were performed to evaluate the influence of CP administration and its timing on the in-hospital survival of COVID-19 patients. RESULTS: A total of 1,498 patients were enrolled in the study; 406 (27%) were administered CP, and 1,092 (73%) were not treated with CP. The propensity score-matched control group consisted of 1,218 subjects. The survival of patients treated with CP was 79%, while that of patients in the matched control group was 62% (P<0.001). Moreover, the chance of survival was significantly greater when CP was administered within three days after the onset of COVID-19 symptoms than when CP was administered after four or more days (87% vs. 76%, P <0.001). In addition, adverse effects related to CP administration were recorded in only 2% of patients and were considered mild in all patients. CONCLUSIONS: Our study demonstrated that the administration of CP was safe and possibly associated with positive effects that were more pronounced if CP was administered within the first three days after the onset of COVID-19 symptoms.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a pasivní imunizace $x metody $7 D007116
- 650 12
- $a COVID-19 $x terapie $x mortalita $7 D000086382
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a sérologická léčba covidu-19 $7 D000093522
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a SARS-CoV-2 $x imunologie $7 D000086402
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Máca, Jan $u Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic $u Institute of Physiology and Pathological Physiology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Sagan, Jiří $u Department of Infectious Diseases, Faculty of Medicine, University of Ostrava and University Hospital Ostrava, Ostrava, Czech Republic $u Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Řezáč, David $u The 7th Field Hospital of the Army of the Czech Republic, Hradec Králové, Czech Republic
- 700 1_
- $a Fridrich, Viktor $u Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Burantová, Anna $u Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Kutáč, Dominik $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Vabroušek, Pavel $u Department of Hematology and Blood Transfusion, Military University Hospital Prague, Prague, Czech Republic
- 700 1_
- $a Kubů, Jan $u Department of Science and Research, University Hospital Bulovka Prague, Prague, Czech Republic
- 700 1_
- $a Chrdle, Aleš $u Department of Infectious Diseases, České Budejovice Hospital, České Budějovice, Czech Republic $u Faculty of Health and Social Sciences, University of South Bohemia, České Budějovice, Czech Republic
- 700 1_
- $a Volfová, Kateřina $u Department of Infectious Diseases, České Budejovice Hospital, České Budějovice, Czech Republic
- 700 1_
- $a Blahutová, Šárka $u Institute of Laboratory Hematology and Transfusion Medicine, Department of Biomedical Sciences, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Rychlík, Ivan $u Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic
- 700 1_
- $a Vonášková, Kateřina $u Department of Internal Medicine, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic
- 700 1_
- $a Majerčin, Radek $u Department of Anesthesiology and Resuscitation, Regional Hospital Jičín, Jičín, Czech Republic
- 700 1_
- $a Králová, Radka $u Department of Anesthesiology and Resuscitation, Regional Hospital Jičín, Jičín, Czech Republic
- 700 1_
- $a Štěpánek, Petr $u Department of Anesthesiology and Resuscitation, Regional Hospital Náchod, Náchod, Czech Republic
- 700 1_
- $a Holub, Michal $u Department of Infectious Diseases, First Faculty of Medicine, Charles University and Military University Hospital Prague, Prague, Czech Republic. michal.holub@uvn.cz $u Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha, U Vojenské nemocnice 1200, Praha 6, 169 06, Czech Republic. michal.holub@uvn.cz
- 773 0_
- $w MED00175136 $t Virology journal $x 1743-422X $g Roč. 21, č. 1 (2024), s. 239
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39350163 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206105124 $b ABA008
- 999 __
- $a ok $b bmc $g 2263695 $s 1240106
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 21 $c 1 $d 239 $e 20240930 $i 1743-422X $m Virology journal $n Virol J $x MED00175136
- GRA __
- $a MO1012 $p Ministerstvo Obrany České Republiky
- GRA __
- $a MO1012 $p Ministerstvo Obrany České Republiky
- LZP __
- $a Pubmed-20250121
